Cargando…

Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids

IMPORTANCE: Buprenorphine is an effective and cost-effective medication to treat opioid use disorder (OUD), but is not readily available to many people with OUD in the US. The current cost-effectiveness literature does not consider interventions that concurrently increase buprenorphine initiation, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Claypool, Anneke L., DiGennaro, Catherine, Russell, W. Alton, Yildirim, Melike F., Zhang, Alan F., Reid, Zuri, Stringfellow, Erin J., Bearnot, Benjamin, Schackman, Bruce R., Humphreys, Keith, Jalali, Mohammad S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199347/
https://www.ncbi.nlm.nih.gov/pubmed/37204803
http://dx.doi.org/10.1001/jamahealthforum.2023.1080
_version_ 1785044913423908864
author Claypool, Anneke L.
DiGennaro, Catherine
Russell, W. Alton
Yildirim, Melike F.
Zhang, Alan F.
Reid, Zuri
Stringfellow, Erin J.
Bearnot, Benjamin
Schackman, Bruce R.
Humphreys, Keith
Jalali, Mohammad S.
author_facet Claypool, Anneke L.
DiGennaro, Catherine
Russell, W. Alton
Yildirim, Melike F.
Zhang, Alan F.
Reid, Zuri
Stringfellow, Erin J.
Bearnot, Benjamin
Schackman, Bruce R.
Humphreys, Keith
Jalali, Mohammad S.
author_sort Claypool, Anneke L.
collection PubMed
description IMPORTANCE: Buprenorphine is an effective and cost-effective medication to treat opioid use disorder (OUD), but is not readily available to many people with OUD in the US. The current cost-effectiveness literature does not consider interventions that concurrently increase buprenorphine initiation, duration, and capacity. OBJECTIVE: To conduct a cost-effectiveness analysis and compare interventions associated with increased buprenorphine treatment initiation, duration, and capacity. DESIGN AND SETTING: This study modeled the effects of 5 interventions individually and in combination using SOURCE, a recent system dynamics model of prescription opioid and illicit opioid use, treatment, and remission, calibrated to US data from 1999 to 2020. The analysis was run during a 12-year time horizon from 2021 to 2032, with lifetime follow-up. A probabilistic sensitivity analysis on intervention effectiveness and costs was conducted. Analyses were performed from April 2021 through March 2023. Modeled participants included people with opioid misuse and OUD in the US. INTERVENTIONS: Interventions included emergency department buprenorphine initiation, contingency management, psychotherapy, telehealth, and expansion of hub-and-spoke narcotic treatment programs, individually and in combination. MAIN OUTCOMES AND MEASURES: Total national opioid overdose deaths, quality-adjusted life years (QALYs) gained, and costs from the societal and health care perspective. RESULTS: Projections showed that contingency management expansion would avert 3530 opioid overdose deaths over 12 years, more than any other single-intervention strategy. Interventions that increased buprenorphine treatment duration initially were associated with an increased number of opioid overdose deaths in the absence of expanded treatment capacity. With an incremental cost- effectiveness ratio of $19 381 per QALY gained (2021 USD), the strategy that expanded contingency management, hub-and-spoke training, emergency department initiation, and telehealth was the preferred strategy for any willingness-to-pay threshold from $20 000 to $200 000/QALY gained, as it was associated with increased treatment duration and capacity simultaneously. CONCLUSION AND RELEVANCE: This modeling analysis simulated the effects of implementing several intervention strategies across the buprenorphine cascade of care and found that strategies that were concurrently associated with increased buprenorphine treatment initiation, duration, and capacity were cost-effective.
format Online
Article
Text
id pubmed-10199347
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-101993472023-05-21 Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids Claypool, Anneke L. DiGennaro, Catherine Russell, W. Alton Yildirim, Melike F. Zhang, Alan F. Reid, Zuri Stringfellow, Erin J. Bearnot, Benjamin Schackman, Bruce R. Humphreys, Keith Jalali, Mohammad S. JAMA Health Forum Original Investigation IMPORTANCE: Buprenorphine is an effective and cost-effective medication to treat opioid use disorder (OUD), but is not readily available to many people with OUD in the US. The current cost-effectiveness literature does not consider interventions that concurrently increase buprenorphine initiation, duration, and capacity. OBJECTIVE: To conduct a cost-effectiveness analysis and compare interventions associated with increased buprenorphine treatment initiation, duration, and capacity. DESIGN AND SETTING: This study modeled the effects of 5 interventions individually and in combination using SOURCE, a recent system dynamics model of prescription opioid and illicit opioid use, treatment, and remission, calibrated to US data from 1999 to 2020. The analysis was run during a 12-year time horizon from 2021 to 2032, with lifetime follow-up. A probabilistic sensitivity analysis on intervention effectiveness and costs was conducted. Analyses were performed from April 2021 through March 2023. Modeled participants included people with opioid misuse and OUD in the US. INTERVENTIONS: Interventions included emergency department buprenorphine initiation, contingency management, psychotherapy, telehealth, and expansion of hub-and-spoke narcotic treatment programs, individually and in combination. MAIN OUTCOMES AND MEASURES: Total national opioid overdose deaths, quality-adjusted life years (QALYs) gained, and costs from the societal and health care perspective. RESULTS: Projections showed that contingency management expansion would avert 3530 opioid overdose deaths over 12 years, more than any other single-intervention strategy. Interventions that increased buprenorphine treatment duration initially were associated with an increased number of opioid overdose deaths in the absence of expanded treatment capacity. With an incremental cost- effectiveness ratio of $19 381 per QALY gained (2021 USD), the strategy that expanded contingency management, hub-and-spoke training, emergency department initiation, and telehealth was the preferred strategy for any willingness-to-pay threshold from $20 000 to $200 000/QALY gained, as it was associated with increased treatment duration and capacity simultaneously. CONCLUSION AND RELEVANCE: This modeling analysis simulated the effects of implementing several intervention strategies across the buprenorphine cascade of care and found that strategies that were concurrently associated with increased buprenorphine treatment initiation, duration, and capacity were cost-effective. American Medical Association 2023-05-19 /pmc/articles/PMC10199347/ /pubmed/37204803 http://dx.doi.org/10.1001/jamahealthforum.2023.1080 Text en Copyright 2023 Claypool AL et al. JAMA Health Forum. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Claypool, Anneke L.
DiGennaro, Catherine
Russell, W. Alton
Yildirim, Melike F.
Zhang, Alan F.
Reid, Zuri
Stringfellow, Erin J.
Bearnot, Benjamin
Schackman, Bruce R.
Humphreys, Keith
Jalali, Mohammad S.
Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
title Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
title_full Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
title_fullStr Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
title_full_unstemmed Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
title_short Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
title_sort cost-effectiveness of increasing buprenorphine treatment initiation, duration, and capacity among individuals who use opioids
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199347/
https://www.ncbi.nlm.nih.gov/pubmed/37204803
http://dx.doi.org/10.1001/jamahealthforum.2023.1080
work_keys_str_mv AT claypoolannekel costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT digennarocatherine costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT russellwalton costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT yildirimmelikef costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT zhangalanf costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT reidzuri costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT stringfellowerinj costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT bearnotbenjamin costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT schackmanbrucer costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT humphreyskeith costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids
AT jalalimohammads costeffectivenessofincreasingbuprenorphinetreatmentinitiationdurationandcapacityamongindividualswhouseopioids